2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1060

Protein Kinase C Inhibitor Generates Human Tolerogenic Dendritic Cells That Induce Tr1 and Foxp3⁺ Regulatory T Cells
Abstract Number: 2317

Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression in CD4+ T Cells
Abstract Number: 2069

Proteinase Activated Receptor-4 Stimulation Promotes Leukocyte Adhesion in the Rat Knee Joint
Abstract Number: 582

Proteomic Analysis of Synovial Tissue: A Unique Tool to Predict Response to Anti-TNF Alpha Therapy in Patients with Inflammatory Arthritis
Abstract Number: 560

Proteomic Profiling of Synovial Fluid Reveals Candidate Psoriatic Arthritis Biomarkers
Abstract Number: 990

Proteomic Shotgun Analysis of Mesenchymal Stem Cells Reveals an Alterated Regulation of Proteosomal Proteins in Osteoarthritis Patients
Abstract Number: 218

Proteomics Study of a Phase 1b Trial with an Anti-IFN-α Monoclonal Antibody Indicates Association of Soluble Interleukin 2 Receptor with Type I Interferon Activity in Patients with Dermatomyositis or Polymyositis
Abstract Number: 2040

Provisions of Quality Driven Care in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2527

Prozone Phenomenon Leads to Low IgG4 Concentrations in IgG4-Related Disease
Abstract Number: 536

Psoriasis and Psoriatic Arthritis in a Diverse Ethnic Cohort
Abstract Number: 1357

Psoriatic Arthritis and Biologic Therapy: Treatment Response, Drug Survival and Outcome After Switching
Abstract Number: 1026

Psoriatic Arthritis and Spondyloarthritis: Inflammation Assessed by “Head to Toe” Wholebody Magnetic Resonance Imaging – A Comparison with Clinical Joint Examination
Abstract Number: 1368

Psoriatic Arthritis in South Asians- Comparison with Caucasians of European Descent
Abstract Number: 1042

Psoriatic Arthritis Patients Assessed by Dynamic Contrast-Enhanced MRI in High Disease Versus Minimal Disease Activity State – a Cross-Sectional Study Correlating Conventional MRI and Clinical Composite Measures
Abstract Number: 2699

Psychosocial Stress and Complement Activation Product C4d On Reticulocytes in Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].